Melatonin in Adults With SMS (SMS-adults)
Primary Purpose
Smith Magenis Syndrome
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Hourly dosing of the nychtemeral secretion of melatonin
Sponsored by
About this trial
This is an interventional screening trial for Smith Magenis Syndrome
Eligibility Criteria
Inclusion Criteria:
- Patient with Smith Magenis Syndrome aged 18 years or older
- subject or guardian having signed the consent
Exclusion Criteria:
- Pregnant women
- Minor subject
- Diagnosis of Smith Magenis syndrome not certain
- Taking benzodiazepines or related substances
- Taking betablockers
- Major behavioral disorders versus indicating participation in this study
Sites / Locations
- CH Le Vinatier
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
10 adult patients with SMS
Arm Description
Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
Outcomes
Primary Outcome Measures
24h melatonin levels
Plasmatic melatonin level will be assessed every hour during 24h for each subject
Secondary Outcome Measures
Analysis of actimetry
At the end of the Visit 1 interview, an actimeter will be given to the patient to be worn on the previous two weeks before Visit 2. This will allow the evaluation of the sleep / wake rhythm in the usual life situation. The actimeter will be reported by the patient during the second visit .
Full Information
NCT ID
NCT03492970
First Posted
March 1, 2018
Last Updated
April 19, 2019
Sponsor
Hôpital le Vinatier
Collaborators
Hospices Civils de Lyon
1. Study Identification
Unique Protocol Identification Number
NCT03492970
Brief Title
Melatonin in Adults With SMS
Acronym
SMS-adults
Official Title
Characterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
March 7, 2018 (Actual)
Primary Completion Date
January 30, 2019 (Actual)
Study Completion Date
March 30, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hôpital le Vinatier
Collaborators
Hospices Civils de Lyon
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sleep-Wake and behavioral disorders in Smith Magenis Syndrome (SMS) are strongly linked to an inversion of the nychtemeral secretion of melatonin. This inversion have been described in children with SMS. However its evolution during adulthood remains unknown. The aim of this study is to assess 24hours melatonin levels in 10 adults with SMS in order to optimize medication in adults with SMS
Detailed Description
SMS is one of the rare syndromes in which the inversion of melatonin secretion is regular, which is an exceptional situation for the study of the influence of genetic factors on the regulation of sleep / wake rhythm. Recently, point mutations of the RAI1 gene (Retinoic Acid Induced 1) have been identified in individuals with the clinical features of SMS with a reversal of the secretion rate of melatonin ,highlighting the role of RAI1 in SMS sleep disorders.
Daytime secretion of melatonin is associated with significant drowsiness and plays a major role in diurnal behavior disorders, especially in younger people. Conversely, the absence of nocturnal melatonin is a causal factor in the shortening and fragmentation of nocturnal sleep .
Basically, little is known about the mechanisms that explain the inversion of the secretion rate of melatonin in SMS.
These aspects, and in particular the nycthemeral reversal of the melatonin cycle, have been described in a population of children and we do not know how these disturbances evolve in adulthood
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smith Magenis Syndrome
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
To specify the evolution of the nycthéméral cycle of the secretion of melatonin in 10 adult subjects carrying a SMS
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
10 adult patients with SMS
Arm Type
Other
Arm Description
Specify the evolution of the nycthemeral cycle of melatonin secretion in adult subjects carrying an SMS Behavioral characterization of adult subjects with SMS Make recommendations on the management of sleep / sleep rhythm disorders and behavior in adult subjects with SMS
Intervention Type
Biological
Intervention Name(s)
Hourly dosing of the nychtemeral secretion of melatonin
Intervention Description
Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
Primary Outcome Measure Information:
Title
24h melatonin levels
Description
Plasmatic melatonin level will be assessed every hour during 24h for each subject
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Analysis of actimetry
Description
At the end of the Visit 1 interview, an actimeter will be given to the patient to be worn on the previous two weeks before Visit 2. This will allow the evaluation of the sleep / wake rhythm in the usual life situation. The actimeter will be reported by the patient during the second visit .
Time Frame
15 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with Smith Magenis Syndrome aged 18 years or older
subject or guardian having signed the consent
Exclusion Criteria:
Pregnant women
Minor subject
Diagnosis of Smith Magenis syndrome not certain
Taking benzodiazepines or related substances
Taking betablockers
Major behavioral disorders versus indicating participation in this study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
POISSON ALICE, PH
Organizational Affiliation
CH LE VINATIER
Official's Role
Principal Investigator
Facility Information:
Facility Name
CH Le Vinatier
City
BRON Cedex
State/Province
Rhône-Alpes
ZIP/Postal Code
69678
Country
France
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Melatonin in Adults With SMS
We'll reach out to this number within 24 hrs